Cognitive Impairment Associated with Schizophrenia - Epidemiology Forecast - 2034
Description
Key Highlights
Cognitive dysfunction is a fundamental aspect of schizophrenia, characterized by moderate to severe impairments across multiple domains. These deficits typically emerge before the onset of overt psychosis and remain stable over the course of the illness in most patients.
Symptoms of CIAS, can include involves deficits in reasoning, problem-solving, social cognition, verbal and visual memory, working memory, attention, and processing speed. Early signs may include reduced motivation, emotional flatness, social withdrawal, and unusual behavior, which can progress to significant cognitive challenges impacting daily life.
In 2024, the total prevalent population of schizophrenia across the 7MM was estimated at approximately 6.2 million cases.
In the s alone, DelveInsight reported approximately 100,000 diagnosed prevalent cases of schizophrenia among adolescents aged 13–17, compared to about 1.8 million cases in adults aged 18 and older—highlighting a significantly greater disease burden, particularly among older adults where the prevalence sharply increases with age.
Japan also contributed meaningfully to the overall prevalence, with an estimated 1.1 million cases of schizophrenia reported in 2024. Notably, CIAS remains a major clinical concern, with the United States representing nearly 50% of the total diagnosed prevalent CIAS cases across the 7MM, highlighting its disproportionate burden and the need for focused cognitive interventions in this region.
Within the EU4 and the UK, Germany led with approximately 275 thousand diagnosed cases of CIAS in 2024, followed by France. In contrast, Italy reported the lowest number of cases, with an estimated 110 thousand—highlighting regional disparities in disease recognition and diagnosis.
From a gender perspective, males accounted for a significantly higher proportion of diagnosed prevalent schizophrenia cases compared to females across the 7MM, suggesting greater severity of illness in men.
Schizophrenia, particularly in its cognitive dimension (CIAS), represents a substantial public health challenge across global markets. The disproportionate burden in countries as well as marked gender and regional disparities, underscore the urgent need for improved screening, early intervention, and standardized approaches to cognitive assessment and treatment.
DelveInsight’s “Cognitive Impairment Associated With Schizophrenia (CIAS) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of CIAS historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Cognitive Impairment Associated With Schizophrenia: Disease Understanding
Cognitive Impairment Associated With Schizophrenia Overview, and Diagnosis
Cognitive impairment is a key feature of schizophrenia, marked by deficits in memory, attention, comprehension, and executive function, significantly affecting daily functioning and rehabilitation outcomes.
CIAS is clinically relevant in approximately 85% of individuals with schizophrenia, with cognitive deficits often appearing early and sometimes fully developing by the first episode. Common symptoms include hallucinations, delusions, agitation, aggression, slowed thinking, and anxiety.
Diagnosing CIAS involves diagnostic tests, a clinical and cognitive assessment, and a detailed medical and psychiatric history. Cognitive deficits are screened using tools like the Montreal Cognitive Assessment (MoCA) or Brief Assessment of Cognition in Schizophrenia (BACS). For a more thorough evaluation, the MATRICS Consensus Cognitive Battery (MCCB) assesses neurocognitive and social cognitive domains. Regular follow-up assessments are crucial to track cognitive changes and treatment responses.
Cognitive Impairment Associated With Schizophrenia Epidemiology
The CIAS epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of schizophrenia, total diagnosed prevalent cases of schizophrenia, total diagnosed prevalent cases of CIAS, and gender-specific diagnosed prevalent cases of schizophrenia patients in the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
In 2024, the total diagnosed prevalent population of schizophrenia across the 7MM was approximately 4.4 million cases.
In the US, schizophrenia exhibited a gender disparity, with males accounting for about 1.3 million diagnosed prevalent cases, compared to approximately 670 thousand among females in 2024.
The US reported the highest burden of CIAS among the 7MM, with an estimated 1.6 million diagnosed prevalent cases in 2024.
Among the EU4 and the UK, Germany accounted for the highest number of diagnosed CIAS cases in 2024, with roughly 270 thousand cases, followed by the UK and France. Italy reported the lowest, with approximately 110 thousand cases.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease incidence.
DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Johns Hopkins Schizophrenia Center, USA, US; University Medicine Essen - Ruhrlandklinik, Germany; Institut Curi, France; Università Politecnica delle Marche Home, Italy; Arnau de Vilanova University Hospital, Spain; Cambridge Psychosis Centre, UK; National Center of Neurology and Psychiatry, Japan and others were contacted. Their opinion helps understand and validate current disease incidence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Scope of the Report
The report covers a segment of an executive summary, and a descriptive overview of CIAS explaining its causes, signs and symptoms, pathogenesis.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Cognitive Impairment Associated With Schizophrenia Report Insights
Patient Population
Country-wise Epidemiology Distribution
Cognitive Impairment Associated With Schizophrenia Report Key Strengths
Ten-year Forecast
The 7MM Coverage
CIAS Epidemiology Segmentation
Cognitive Impairment Associated With Schizophrenia Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of CIAS? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CIAS?
What is the historical and forecasted CIAS patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What is the diagnostic pattern of CIAS?
Which clinical factors will affect CIAS?
Which factors will affect the increase in the diagnosis of CIAS?
Reasons to buy
Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the change in CIAS cases in varying geographies over the coming years.
A detailed overview of total prevalent cases of schizophrenia, total diagnosed prevalent cases of schizophrenia, total diagnosed prevalent cases of CIAS, and gender-specific diagnosed prevalent cases of schizophrenia is included.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Cognitive dysfunction is a fundamental aspect of schizophrenia, characterized by moderate to severe impairments across multiple domains. These deficits typically emerge before the onset of overt psychosis and remain stable over the course of the illness in most patients.
Symptoms of CIAS, can include involves deficits in reasoning, problem-solving, social cognition, verbal and visual memory, working memory, attention, and processing speed. Early signs may include reduced motivation, emotional flatness, social withdrawal, and unusual behavior, which can progress to significant cognitive challenges impacting daily life.
In 2024, the total prevalent population of schizophrenia across the 7MM was estimated at approximately 6.2 million cases.
In the s alone, DelveInsight reported approximately 100,000 diagnosed prevalent cases of schizophrenia among adolescents aged 13–17, compared to about 1.8 million cases in adults aged 18 and older—highlighting a significantly greater disease burden, particularly among older adults where the prevalence sharply increases with age.
Japan also contributed meaningfully to the overall prevalence, with an estimated 1.1 million cases of schizophrenia reported in 2024. Notably, CIAS remains a major clinical concern, with the United States representing nearly 50% of the total diagnosed prevalent CIAS cases across the 7MM, highlighting its disproportionate burden and the need for focused cognitive interventions in this region.
Within the EU4 and the UK, Germany led with approximately 275 thousand diagnosed cases of CIAS in 2024, followed by France. In contrast, Italy reported the lowest number of cases, with an estimated 110 thousand—highlighting regional disparities in disease recognition and diagnosis.
From a gender perspective, males accounted for a significantly higher proportion of diagnosed prevalent schizophrenia cases compared to females across the 7MM, suggesting greater severity of illness in men.
Schizophrenia, particularly in its cognitive dimension (CIAS), represents a substantial public health challenge across global markets. The disproportionate burden in countries as well as marked gender and regional disparities, underscore the urgent need for improved screening, early intervention, and standardized approaches to cognitive assessment and treatment.
DelveInsight’s “Cognitive Impairment Associated With Schizophrenia (CIAS) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of CIAS historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Cognitive Impairment Associated With Schizophrenia: Disease Understanding
Cognitive Impairment Associated With Schizophrenia Overview, and Diagnosis
Cognitive impairment is a key feature of schizophrenia, marked by deficits in memory, attention, comprehension, and executive function, significantly affecting daily functioning and rehabilitation outcomes.
CIAS is clinically relevant in approximately 85% of individuals with schizophrenia, with cognitive deficits often appearing early and sometimes fully developing by the first episode. Common symptoms include hallucinations, delusions, agitation, aggression, slowed thinking, and anxiety.
Diagnosing CIAS involves diagnostic tests, a clinical and cognitive assessment, and a detailed medical and psychiatric history. Cognitive deficits are screened using tools like the Montreal Cognitive Assessment (MoCA) or Brief Assessment of Cognition in Schizophrenia (BACS). For a more thorough evaluation, the MATRICS Consensus Cognitive Battery (MCCB) assesses neurocognitive and social cognitive domains. Regular follow-up assessments are crucial to track cognitive changes and treatment responses.
Cognitive Impairment Associated With Schizophrenia Epidemiology
The CIAS epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of schizophrenia, total diagnosed prevalent cases of schizophrenia, total diagnosed prevalent cases of CIAS, and gender-specific diagnosed prevalent cases of schizophrenia patients in the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
In 2024, the total diagnosed prevalent population of schizophrenia across the 7MM was approximately 4.4 million cases.
In the US, schizophrenia exhibited a gender disparity, with males accounting for about 1.3 million diagnosed prevalent cases, compared to approximately 670 thousand among females in 2024.
The US reported the highest burden of CIAS among the 7MM, with an estimated 1.6 million diagnosed prevalent cases in 2024.
Among the EU4 and the UK, Germany accounted for the highest number of diagnosed CIAS cases in 2024, with roughly 270 thousand cases, followed by the UK and France. Italy reported the lowest, with approximately 110 thousand cases.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease incidence.
DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Johns Hopkins Schizophrenia Center, USA, US; University Medicine Essen - Ruhrlandklinik, Germany; Institut Curi, France; Università Politecnica delle Marche Home, Italy; Arnau de Vilanova University Hospital, Spain; Cambridge Psychosis Centre, UK; National Center of Neurology and Psychiatry, Japan and others were contacted. Their opinion helps understand and validate current disease incidence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Scope of the Report
The report covers a segment of an executive summary, and a descriptive overview of CIAS explaining its causes, signs and symptoms, pathogenesis.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Cognitive Impairment Associated With Schizophrenia Report Insights
Patient Population
Country-wise Epidemiology Distribution
Cognitive Impairment Associated With Schizophrenia Report Key Strengths
Ten-year Forecast
The 7MM Coverage
CIAS Epidemiology Segmentation
Cognitive Impairment Associated With Schizophrenia Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of CIAS? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CIAS?
What is the historical and forecasted CIAS patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What is the diagnostic pattern of CIAS?
Which clinical factors will affect CIAS?
Which factors will affect the increase in the diagnosis of CIAS?
Reasons to buy
Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the change in CIAS cases in varying geographies over the coming years.
A detailed overview of total prevalent cases of schizophrenia, total diagnosed prevalent cases of schizophrenia, total diagnosed prevalent cases of CIAS, and gender-specific diagnosed prevalent cases of schizophrenia is included.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
67 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Cognitive Impairment Associated With Schizophrenia (CIAS) Patient Overview at a Glance
- 3.1. Patient Share Distribution (%) in the 7MM in 2024
- 3.2. Patient Share Distribution (%) in the 7MM in 2034
- 4. Executive Summary
- 5. Epidemiology Forecast Methodology
- 6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Signs and Symptoms
- 6.3. Causes
- 6.4. Diagnosis and Differential Diagnosis
- 6.4.1. Diagnostic Algorithm
- 6.4.2. Differential Diagnosis
- 6.4.3. Diagnostic Guidelines
- 7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale
- 7.3. Total Diagnosed Prevalent Cases of CIAS in the 7MM
- 7.4. The United States
- 7.4.1. Total Prevalent Cases of Schizophrenia in the US
- 7.4.2. Total Diagnosed Prevalent Cases of Schizophrenia in the US
- 7.4.3. Total Diagnosed Prevalent Cases of CIAS in the US
- 7.4.4. Gender-specific Diagnosed Prevalent Cases of Schizophrenia in the US
- 7.5. EU4 and the UK
- 7.5.1. Total Prevalent Cases of Schizophrenia in EU4 and the UK
- 7.5.2. Total Diagnosed Prevalent Cases of Schizophrenia in EU4 and the UK
- 7.5.3. Total Diagnosed Prevalent Cases of CIAS in EU4 and the UK
- 7.5.4. Gender-specific Diagnosed Prevalent Cases of Schizophrenia in EU4 and the UK
- 7.6. Japan
- 7.6.1. Total Prevalent Cases of Schizophrenia in Japan
- 7.6.2. Total Diagnosed Prevalent Cases of Schizophrenia in Japan
- 7.6.3. Total Diagnosed Prevalent Cases of CIAS in Japan
- 7.6.4. Gender-specific Diagnosed Prevalent Cases of Schizophrenia in Japan
- 8. KOL Views
- 9. Appendix
- 9.1. Acronyms and Abbreviations
- 9.2. Bibliography
- 9.3. Report Methodology
- 10. DelveInsight Capabilities
- 11. Disclaimer
- 12. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
